EuroPCR 2023 | New Renal Denervation Devices Show Promising Results

The Netrod System study included 205 patients with uncontrolled essential hypertension while taking two drugs (nifedipine and hydrochlorothiazide), who were randomized 2:1 to denervation or sham control. All subjects had undergone renal angiography before randomization.

Renal denervation was done using the Setrod System device.

Mean patient age was 50 years old, and 16% of subjects were female.

In-office blood pressure was about 161/100 mmHg, and 152/96 mmHg during the 24-hour outpatient monitoring.

Those who underwent renal denervation more frequently reached the target blood pressure, 140/90 mmHg (64.7% vs. 7.7%; p = <0.0001), and a reduction of at least 5 mmHg in systolic blood pressure in the office setting (93.4% vs. 60%; p ≤ 0.0001).

Denervation-related complications were few. Only one patient presented a renal artery dissection, but it was related to catheterization.

Read also: EuroPCR 2023 | More Evidence in Favor of Renal Denervation.

Authors conclude that denervation with the Netrod System is safe and effective in patients with essential hypertension.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Reference: The Netrod System, presentado por el Dr. Fei Gao en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...